Trial reportCirculation1991
Effects of colestipol-niacin therapy on human femoral atherosclerosis.
Trial report in Circulation, 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00000599. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Cholesterol-Lowering Atherosclerosis Study (CLAS)
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 173 citations in OpenAlex.
- Lipid-lowering for peripheral arterial disease of the lower limb.The Cochrane database of systematic reviews · 2007Pooled it
- The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT).Atherosclerosis · 2013Trial
- Research trends in lipid-lowering therapies for coronary heart disease combined with hyperlipidemia: a bibliometric study and visual analysis.Frontiers in pharmacology · 2024Article
- Focus on the Prevention of Acute Limb Ischemia: Centrality of the General Practitioner from the Point of View of the Internist.Journal of clinical medicine · 2023Review
- Synthesis, Docking, Computational Studies, and Antimicrobial Evaluations of New Dipeptide Derivatives Based on Nicotinoylglycylglycine Hydrazide.Molecules (Basel, Switzerland) · 2020Article
- Dyslipidemia Profiles in Patients with Peripheral Artery Disease.Current cardiology reports · 2019Review
- G protein-coupled receptors for energy metabolites as new therapeutic targets.Nature reviews. Drug discovery · 2012Review
- Niacin inhibits skin dendritic cell mobilization in a GPR109A independent manner but has no impact on monocyte trafficking in atherosclerosis.Immunobiology · 2012Article
- LDL lowering in peripheral arterial disease: are there benefits beyond reducing cardiovascular morbidity and mortality?Clinical lipidology · 2012Article
- Does nicotinic acid (niacin) lower blood pressure?International journal of clinical practice · 2009Review
- Peripheral arterial occlusive disease: magnetic resonance imaging and the role of aggressive medical management.World journal of surgery · 2007Review
- The "Statinth" wonder of the world: a panacea for all illnesses or a bubble about to burst.Journal of negative results in biomedicine · 2005Review
- Niacin dosing: relationship to benefits and adverse effects.Current atherosclerosis reports · 2000Review
- Peripheral Arterial Disease.Current treatment options in cardiovascular medicine · 1999Article
- Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level.The Journal of clinical investigation · 1994Article
- Lowering blood lipids to treat atherosclerosis: vascular tone, plaques, events, and mortality.Cardiovascular drugs and therapy · 1993Article
- Atherosclerosis--reversal with therapy.The Western journal of medicine · 1993Review
- Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
The 2-year therapy effect on femoral atherosclerosis was evaluated in the Cholesterol Lowering Atherosclerosis Study (CLAS), a randomized, placebo-plus-diet-controlled angiographic trial of colestipol-niacin therapy plus diet in men with previous coronary bypass surgery. Different diet compositions were prescribed to enhance the differential in blood cholesterol responses between the two groups. The annual rate of change in computer-estimated atherosclerosis (CEA), a measure of lumen abnormality, was evaluated between treatment groups. A significant per-segment therapy effect was found in segments with moderately severe atherosclerosis (p less than 0.04) and in proximal segments (p less than 0.02). When segmental CEA measures were combined into a per-patient score using an adaptation of the National Heart, Lung, and Blood Institute scoring procedure, a significant therapy effect was observed (p less than 0.02). Total variance of the annual change rate in CEA was as predicted from pilot studies, but measurement variation was larger. The therapy effect observed in femoral arteries, although significant, was less marked than the strong and consistent benefit previously reported for both native coronary arteries and aortocoronary bypass grafts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.